High-throughput Drug Repositioning for the Discovery of New Treatments for Chagas Disease

Author(s): Carolina L. Bellera, Maria L. Sbaraglini, Dario E. Balcazar, Laura Fraccaroli, M. Cristina Vanrell, A. Florencia Casassa, Carlos A. Labriola, Patricia S. Romano, Carolina Carrillo, Alan Talevi.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 15 , Issue 3 , 2015

Become EABM
Become Reviewer

Abstract:

Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, which were developed more than 40 years ago and present important efficacy and safety limitations. Drug repositioning (i.e. finding second or further therapeutic indications for known drugs) has raised considerable interest within the international drug development community. There are many explanations to the current interest on drug repositioning including the possibility to partially circumvent clinical trials and the consequent saving in time and resources. It has been suggested as a particular attractive approach for the development of novel therapeutics for neglected diseases, which are usually driven by public or non-profit organizations. Here we review current computer-guided approaches to drug repositioning and reports on drug repositioning stories oriented to Chagas disease, with a focus on computer-guided drug repositioning campaigns.

Keywords: Chagas disease, computer-guided drug repositioning, drug repositioning, drug repurposing, neglected diseases, indication expansion, high-throughput drug repurposing.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2015
Page: [182 - 193]
Pages: 12
DOI: 10.2174/138955751503150312120208
Price: $58

Article Metrics

PDF: 46
HTML: 2